Copyright
©The Author(s) 2019.
World J Stem Cells. Apr 26, 2019; 11(4): 212-221
Published online Apr 26, 2019. doi: 10.4252/wjsc.v11.i4.212
Published online Apr 26, 2019. doi: 10.4252/wjsc.v11.i4.212
Table 1 Indication of autologous hematopoietic stem cell transplantation in autoimmune diseases
| Indication | Level of recommendation | Level of evidence |
| Systemic sclerosis | Clinical opportunity: a careful evaluation of the benefit / risk ratio is required | I |
| Multiple sclerosis | II | |
| Chronic inflammatory demyelinating polyneuropathy | II | |
| Myasthenia gravis | II | |
| Crohn's disease | II | |
| Systemic lupus erythematosus | II | |
| Rheumatoid arthritis | II | |
| Juvenile idiopathic arthritis | II | |
| Autoimmune cytopenias | II | |
| Polymyositis/dermatomyositis | III | |
| Vasculitides | III | |
| Neuromyelitis optica | III | |
| Paraneoplastic neurological symptoms | III | |
| Type 1 diabetes mellitus | Under construction | III |
| Refractory celiac disease | III |
- Citation: Műzes G, Sipos F. Issues and opportunities of stem cell therapy in autoimmune diseases. World J Stem Cells 2019; 11(4): 212-221
- URL: https://www.wjgnet.com/1948-0210/full/v11/i4/212.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v11.i4.212